NASDAQ: MREOMereo Biopharma Group PLC Stock Ownership - Who owns Mereo Biopharma Group?
Insider buying vs selling
Have Mereo Biopharma Group PLC insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| John A. Lewicki | Chief Scientific Officer | 2024-09-13 | 10,937 | $4.22 | $46.17kSell |
| Denise Scotsknight | Chief Executive Officer | 2024-09-13 | 60,046 | $4.22 | $253.45kSell |
| Christine Ann Fox | Chief Financial Officer | 2024-09-13 | 19,158 | $4.22 | $80.87kSell |
| Alexandra Hugheswilson | Chief Patient Access and Commercial Planning | 2024-09-13 | 16,304 | $4.22 | $68.82kSell |
| Alexandra Hugheswilson | Chief Patient Access and Commercial Planning | 2024-09-13 | 84,008 | $4.22 | $354.60kSell |
| Charles Sermon | General Counsel | 2024-09-13 | 20,946 | $4.22 | $88.41kSell |
| Denise Scotsknight | Chief Executive Officer | 2024-09-12 | 28,611 | $4.47 | $127.98kSell |
| Charles Sermon | General Counsel | 2024-09-12 | 9,980 | $4.47 | $44.64kSell |
| John A. Lewicki | Chief Scientific Officer | 2024-09-12 | 5,212 | $4.47 | $23.31kSell |
| Christine Ann Fox | Chief Financial Officer | 2024-09-12 | 9,128 | $4.47 | $40.83kSell |
MREO insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when MREO insiders and whales buy or sell their stock.
MREO Shareholders
What type of owners hold Mereo Biopharma Group PLC stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Rubric Capital Management LP | 4.02% | 31,950,000 | $80.51M | Insider |
| Janus Henderson Group PLC | 2.15% | 17,122,563 | $43.15M | Institution |
| Rubric Capital Management LP | 1.93% | 15,307,347 | $38.57M | Institution |
| Rock Springs Capital Management LP | 1.21% | 9,599,170 | $24.19M | Institution |
| Adage Capital Partners GP LLC | 1.10% | 8,715,013 | $21.96M | Institution |
| Mangrove Partners IM LLC | 1.09% | 8,636,485 | $21.76M | Institution |
| Deerfield Management Company LP Series C | 0.84% | 6,710,429 | $16.91M | Institution |
| Frazier Life Sciences Management LP | 0.64% | 5,097,779 | $12.85M | Institution |
| Alkeon Capital Management LLC | 0.59% | 4,698,100 | $11.84M | Institution |
| 683 Capital Management LLC | 0.57% | 4,550,000 | $11.47M | Institution |
MREO vs Biotech Stocks
Mereo Biopharma Group Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.